Program
lisdexamfetamine
Also written as “SPD489”, “NRP104” and “SPD489 (Lisdexamfetamine dimesylate)”.
Its studies are mostly in Attention Deficit Disorder with Hyperactivity · Schizophrenia · Depressive Disorder, Major · Binge-Eating Disorder · Sleep Deprivation, led by 3 companies.
Drug pageLisdexamfetamine: every studyAll 97 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Takedaits history only | 450 open or running | phase 4since Jul 10, 2007 | Oct 31, 2005 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Jul 25, 2025 | Jul 25, 2025 | none ahead |
| Knoa Pharma | 10 open or running | phase 3since Aug 28, 2015 | Aug 28, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Knoa Pharma only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 28, 2015First study: phase 3 study in Attention Deficit Disorder with HyperactivityFirst studyNCT02555150 · 40 enrolled · United States
TargetBeta
“Dopamine transporter releasing agent; Norepinephrine transporter releasing agent; Synaptic vesicular amine transporter inhibitor”ChEMBL 37, by rule
Studies
The one study Knoa Pharma leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT02555150Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | Jan 2017 | 40 |
How it is read
Names in the registry
- “SPD489”, 6 entries
- “NRP104”, 6 entries
- “SPD489 (Lisdexamfetamine dimesylate)”, 5 entries
- “Lisdexamfetamine dimesylate”, 5 entries
- “Lisdexamfetamine Dimesylate”, 4 entries
Conditions, from the studies’ own filings
- Attention Deficit Disorder with Hyperactivity, 25 studies
- Schizophrenia, 6 studies
- Depressive Disorder, Major, 6 studies
- Binge-Eating Disorder, 5 studies
- Sleep Deprivation, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.